Bruker Corporation

NASDAQ:BRKR

Medical - Devices

Healthcare
$63.26 -1.92%

-$1.07 today

Market cap
$9.66B
Beta
1.30
P/E (TTM)
-718.1
EPS (TTM)
-$0.08
Dividend yield
0.37%
52W Low $28.53High $64.54

Volume 1.73M

Average 2.41M

BRKR Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Bruker CorporationNASDAQ: BRKR

Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026

Depreciation & amortization grows, but more slowly than its trailing trend

Q2 FY2026 depreciation & amortization of $58M rose 3.4% year over year, behind the +9.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 0.5% from the prior quarter. Over 3 fiscal years it compounded at +35.4% a year.

Context

  • Depreciation & amortization amounted to 6.4% of revenue in FY2025, up 1.0 pp from a year earlier.
  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +3.4% toward the trailing-twelve-month pace of +9.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$58M-0.5% QoQ
Last fiscal yearDec 2025
$220.3M+19.9% YoY
LTMJun 2026
$230.1M+9.4% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.4%——
1 year+19.9%——
3-year CAGR+35.4%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
220.3M USD
Year-over-year change
+19.9%
4-year CAGR
+25.4%

Depreciation & Amortization vs competitors

How BRKR compares with its peers on the latest reported figures

  • BRKR's LTM Jun 2026 depreciation & amortization of $230.1M is the 6th largest of the 11 companies compared; the peer median is $236.56M.
  • Its year-over-year change of +9.4% is the 3rd highest of 11, against a peer median of -2.7%.
  • Depreciation & amortization amounts to 6.6% of revenue for BRKR, versus a peer median of 7.7%.
BRKR Competitors Peer median
Depreciation & Amortization for BRKR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TMOThermo Fisher Scientific Inc.LTM Sep 2026$3.11B +11.2%-6.3%6.6%
DHRDanaher CorporationLTM Sep 2026$1.91B -21.1%+4.7%7.5%
WATWaters CorporationLTM Jul 2026$613.22M +211.1%+16.5%13.2%
RVTYRevvity, Inc.LTM Jul 2026$412.24M -0.2%-1.7%14.2%
AAgilent Technologies, Inc.LTM Jul 2026$271M -5.2%-3.1%3.7%
BRKRBruker CorporationLTM Jun 2026$230.1M +9.4%+35.4%6.6%
QGENQiagen N.V.LTM Jun 2026$202.13M +7.0%-2.4%9.6%
MTDMettler-Toledo International Inc.LTM Jun 2026$131M +7.3%+3.6%3.2%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$127.6M -23.5%+6.4%4.9%
TECHBio-Techne CorporationLTM Sep 2026$96.75M -8.8%-3.2%7.9%
PACBPacific Biosciences of California, Inc.LTM Mar 2026$17.69M -95.7%+181.5%11.1%
Peer median (excluding BRKR) $236.56M-2.7%+0.9%7.7%

Competitors are the stored peer set for BRKR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income280.6M298.5M427.2M113.8M(8.3M)
Depreciation & Amortization89.1M88.7M114.9M183.8M220.3M
Deferred Income Tax(5.8M)(14.8M)(24.4M)(63.8M)(104.5M)
Stock-Based Compensation17.2M27.7M24M25.3M20.2M
Change in Working Capital(125.2M)(144.1M)(87.8M)(78.2M)(144.8M)
Accounts Receivables(95.3M)(67.9M)(900K)(40.6M)54.2M
Inventory(67M)(137.9M)(125M)(69.8M)12.1M
Accounts Payables61.8M33.3M23.1M20.8M(37.5M)
Other Working Capital(24.7M)28.4M15M11.4M(173.6M)
Other Non-Cash Items26.5M18.4M(103.8M)70.4M151.2M
Operating Cash Flow282.4M274.4M350.1M251.3M134.1M
Capital Expenditures(92M)(129.2M)(106.9M)(115.3M)(120.2M)
Acquisitions (Net)(65M)(182.3M)(226.6M)(1.6B)(73.9M)
Purchases of Investments(148.5M)(60.2M)(24.8M)(48.3M)(7.2M)
Sales of Investments108.2M106.2M21.2M4.8M0
Other Investing Activities4.9M13.9M11.1M1.1M(24.6M)
Investing Cash Flow(192.4M)(251.6M)(326M)(1.76B)(196.5M)
Debt Repayment489.7M(110.7M)(21.5M)875.9M(491.3M)
Common Stock Issued7M2.8M9.5M403M669.7M
Common Stock Repurchased(153.3M)(263.1M)(152.3M)0(10M)
Dividends Paid(24.2M)(29.8M)(29.4M)(30.2M)(22.8M)
Other Financing Activities(500K)(14.5M)300K(18.9M)(10.5M)
Financing Cash Flow318.7M(415.3M)(193.4M)1.23B135.1M
Effect of Forex Changes(22.5M)(30.5M)12.2M(28.7M)43.7M
Net Change in Cash386.2M(423M)(157.1M)(304.9M)116.4M
Free Cash Flow190.4M145.2M243.2M136M13.9M

Bruker Corporation

NASDAQ:BRKR

Intrinsic Alpha fair value

Locked

Current Price

$63.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.